Effect of miR-21 in promoting angiogenesis differentiation of umbilical cord blood mesenchymal stem cells in vitro

doi:10.19439/j.sjos.2017.05.002

Abstract

Abstract: PURPOSE: To investigate the effect of miR-21 on promoting vascular differentiation of umbilical cord blood derived mesenchymal stem cells (UCBMSCs) in vitro. METHODS: UCBMSCs (from Stem Cell Bank of Tongji University) were cultured; Lenti-LacZ-Luciferase and Lenti-miR-21-Luciferase Lentiviral vector were reconstructed; Real-time fluorescence quantification PCR and Western blot were performed to detect the expression of key angiogenic factors at 0, 1, 4, 7 and 14 d after target gene was transduced into UCBMSCs; UCBMSCs of the third generation were transduced with Lenti-LacZ-Luciferase and Lenti-miR-21- Luciferase; matrigel tube assay was performed to observe the tube-like structure under microscope. The data were statistically analyzed using Student's t test and variance analysis with SPSS13.0 software package. RESULTS: UCBMSCs were successfully cultured; The results of qPCR and Western blot showed the expression of HIF-1α and VEGF in miR-21 group significantly increased at 4 d and continued until 7 d and 14 d; Matrigel results showed the tubular structures in Lenti-miR-21-Luciferase group were more than other groups both in amount and in length. CONCLUSIONS: MiR-21 can promote vascular differentiation of UCBMSCs.

Key words: miR-21, UCBMSCs, Angiogenesis

CLC Number:

R329

TIAN Zhong-kui, LIU Lin, CHEN Dong-lei, WANG Pei, XU Jing-ming, TANG Yi, TANG Chun-bo. Effect of miR-21 in promoting angiogenesis differentiation of umbilical cord blood mesenchymal stem cells in vitro[J]. Shanghai Journal of Stomatology, 2017, 26(5): 471-475.

References

[1] Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Society for Cardiovascular Angiography and Interventions,Society of Interventional Radiology,Society for Vascular Medicine, and Society for Vascular Surgery [J]. J Vasc Surg, 2011, 54(5): e32-58.
[2] Sutton MT, Bonfield TL. Stem cells: innovations in clinical applications [J]. Stem Cells Int, 2014, 2014: 516278.
[3] Chung DJ, Choi CB, Lee SH, et al. Intraarterially delivered human umbilical cord blood-derived mesenchymal stem cells in canine cerebral ischemia [J]. J Neurosci Res, 2009, 87(16): 3554-3567.
[4] Lee OK, Kuo TK, Chen WM, et al. Isolation of multipotent mesenchymal stem cells from umbilical cord blood [J]. Blood, 2004, 103(5): 1669-1675.
[5] Caporali A, Emanueli C. MicroRNA regulation in angiogenesis [J]. Vascul Pharmacol, 2011, 55(4): 79-86.
[6] Selcuklu SD, Donoghue MT, Spillane C. miR-21 as a key regulator of oncogenic processes [J]. Biochem Soc Trans, 2009, 37(4): 918-925.
[7] Richart A, Loyer X, Néri T, et al. MicroRNA-21 coordinates human multipotent cardiovascular progenitors therapeutic potential [J]. Stem Cells, 2014, 32(11): 2908-2922.
[8] Madonna R, De Caterina R. Stem cells and growth factor delivery systems for cardiovascular disease [J]. J Biotechnol, 2011, 154(4): 291-297.
[9] Yang HN, Choi JH, Park JS, et al. Differentiation of endothelial progenitor cells into endothelial cells by heparin-modified supramolecular pluronic nanogels encapsulating bFGF and complexed with VEGF165 genes [J]. Biomaterials, 2014, 35(16): 4716-4728.
[10] Lee M, Jeong SY, Ha J, et al. Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo [J]. Biochem Biophys Res Commun, 2014, 446(4): 983-989.
[11] Gluckman E, Ruggeri A, Volt F, et al. Milestones in umbilical cord blood transplantation [J]. Br J Haematol, 2011, 154(4): 441-447.
[12] Gao W, Xu J, Liu L, et al. A systematic analysis of predicted miR-21 targets identifies a signature for lung cancer [J]. Biomed Pharmacother, 2012, 66(1): 21- 28.
[13] Qian X, Long L, Shi Z, et al. Star-branched amphiphilic PLA-b- PDMAEMA copolymers for co-delivery of miR-21 inhibitor and doxorubicin to treat glioma [J]. Biomaterials, 2014, 35(7): 2322-2335.
[14] Liu LZ, Li C, Chen Q, et al. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression [J]. PLoS One, 2011, 6(4): e19139.
[15] Akagi I, Okayama H, Schetter AJ, et al. Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma [J].Cancer Res, 2013, 73(13): 3821-3832.
[16] Wei Y, Schober A, Weber C. Pathogenic arterial remodeling: the good and bad of microRNAs [J]. Am J Physiol Heart Circ Physiol, 2013, 304(8): H1050- 1059.
[17] Ji R, Cheng Y, Yue J, et al. MicroRNA expression signature and antisense- mediated depletion reveal an essential role of MicroRNA in vascular neointimal lesion formation [J]. Circ Res, 2007, 100(11): 1579-1588.
[18] Zou DH, Zhang ZY, Ye DX, et al. Repair of critical-sized rat calvarial defects using genetically engineered bone marrow-derived mesenchymal stem cells overexpressing hypoxia-inducible factor-1α [J]. Stem Cells, 2011, 29(9): 1380-1390.
[19] Zhang Z, Li Z, Gao C, et al. miR-21 plays a pivotal role in gastric cancer pathogenesis and progression [J]. Lab Invest, 2008, 88(12): 1358-1366.
[20] Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21